COMMUNIQUÉS West-GlobeNewswire

Apellis Pharmaceuticals Announces First Patient Dosed in Its Phase 3 Clinical Program for APL-2 in Patients With Geographic Atrophy
12/09/2018
CRESTWOOD, Ky. and WALTHAM, Mass., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to [...]
Helix BioPharma Corp. collaborator ProMab Biotechnologies Publishes Paper on Multiple Myeloma CAR-T
12/09/2018
RICHMOND HILL, Ontario, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX:HBP), (FSE:HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and [...]
Trillium Therapeutics Announces Data Presentations at Upcoming Scientific Meetings
12/09/2018
Updated safety and efficacy data from the TTI-621 intravenous trial at the 16th Annual Discovery on Target Conference Updated data from the TTI-621 intralesional trial in patients with mycosis fungoides and Sézary [...]
RedHill Biopharma Announces Positive End-of-Phase II Meeting with FDA on BEKINDA® for IBS-D
12/09/2018
The positive Type B meeting with the FDA followed a successful Phase II study of BEKINDA ® for diarrhea-predominant irritable bowel syndrome (IBS-D), one of the most common gastrointestinal disorders In light of the [...]
Asterias Provides 24 Month Cohort 2 Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury
12/09/2018
FREMONT, Calif., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions [...]
Pernix Therapeutics Holdings, Inc.’s Subsidiaries File Notice of Appeal in Patent Litigation Concerning Zohydro® ER with BeadTek®
12/09/2018
MORRISTOWN, N.J., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), announced today that, on September 7, 2018, its subsidiaries, Pernix Therapeutics, LLC, a specialty pharmaceutical [...]
Inivata Strengthens Senior Leadership Ahead of Next Stage of Company Growth
12/09/2018
Inivata Strengthens Senior Leadership Ahead of Next Stage of Company Growth Research Triangle Park, NC and Cambridge, UK, September 12, 2018 -- Inivata , a leader in liquid biopsy, today announces the strengthening of [...]
Aleafia Completes Second Harvest with Sale to Licensed Producer Imminent
12/09/2018
Clinic Operations and Cannabis Sales Providing Immediate Multiple Income Streams TORONTO, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Aleafia Health Inc. (TSXV: ALEF; OTCQX: ALEAF, FRA: ARAH) (“Aleafia“) or (the “Company“), one [...]
Cyclacel Pharmaceuticals Appoints Robert J. Spiegel, M.D. to Board of Directors
12/09/2018
- Former CMO of Schering-Plough Joins Cyclacel Board - BERKELEY HEIGHTS, N.J., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a [...]
EyePoint Pharmaceuticals Reports Fiscal 2018 Fourth Quarter & Full Year Financial Results and Highlights Recent Progress
12/09/2018
-Substantial progress made in the Company’s accelerated transformation into a commercial entity -YUTIQ™ PDUFA date of November 5, 2018 -Commercial preparations underway for launch of DEXYCU™ in the first half of [...]
Acarix gains market acceptance in Austria; new customers orders CADScor®System for ruling out Coronary Artery Disease (CAD).
12/09/2018
Press release Malmö, September 12, 2018 Acarix gains market acceptance in Austria; new customers orders CADScor®System for ruling out Coronary Artery Disease (CAD). Acarix AB (publ) ("Acarix") reports first sales in [...]
Vital Therapies Announces That Topline Results of VTL-308 Fail to Achieve Primary and Secondary Endpoints of Improvement in Survival
12/09/2018
SAN DIEGO, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq: VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced [...]
Solon Eiendom ASA – Primary insider notification
12/09/2018
(Oslo, Norway, September 11, 2018) Solon Eiendom ASA Board Member Tore Aksel Voldberg has today through his wholly owned company Dukat AS bought 30.000 shares in Solon Eiendom ASA at a price of NOK 29. Following this [...]
Shire plc : Rule 2.9 Announcement
12/09/2018
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 12 September 2018 [...]
Verona Pharma to Present Expanded Dataset from RPL554 Phase 2b Clinical Trial in COPD at European Respiratory Society International Congress
12/09/2018
Late breaking oral presentation will provide additional detail around previously reported top-line results LONDON, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a [...]
Shire Granted EU Marketing Authorization for Veyvondi® for Adults With Von Willebrand Disease
12/09/2018
SHIRE GRANTED EU MARKETING AUTHORIZATION FOR VEYVONDI ® [VONICOG ALFA, RECOMBINANT VON WILLEBRAND FACTOR] FOR ADULTS WITH VON WILLEBRAND DISEASE Marketing Authorization will enable patient access to VEYVONDI ® [...]
Notice of Changes in the Supervisory Council of JSC Olainfarm
12/09/2018
The Joint Stock Company Olainfarm hereby informs about the receipt of the notice from the member of the Council of the Joint Stock Company "Olainfarm" Signe Baldere-Sildedze on leaving the Supervisory Council as of [...]
DBV Technologies Announces Positive DSMB Review of Part A of Phase III Study in Peanut-Allergic Toddlers
12/09/2018
Montrouge, France, September 12, 2018 DBV Technologies Announces Positive DSMB Review of Part A of Phase III Study in Peanut-Allergic Toddlers No safety concerns identified by independent DSMB Part B expected to [...]
DBV Technologies annonce la revue positive par le DSMB des résultats du premier volet de sa phase III réalisé sur de jeunes enfants allergiques à l'arachide
12/09/2018
Montrouge, France, le 12 septembre (07h30 CEST), 2018 DBV Technologies annonce la revue positive par le DSMB des résultats du premier volet de sa phase III réalisé sur de jeunes enfants allergiques à l'arachide Le DSMB [...]

Pages